Seems BTG (the investment Co. has gone elsewhere leaving EPIC available for BTG (The Bio-Medico) to move their EPIC.

Whilst Historic graphs appear to have been retained, it seems MoneyAM can't move the Investor-comments section....?

. . . . DYOR . . .

BTG (medico) is the one with Varisolve (Varicose vein treatment) which took off spectacularly (Ho-Ho) nearly a year ago). They have several on-going medical products/treatm,ents which appear to be receiving milestones /income.

Yet, BTG trades on a big PE-ratio.

A couple of years ago they merged sweetly with Protherics (Snake anti-venom) which had an income but little new prospects . . . the joining suited most shareholders at the time.
. . . . but ignore anything I say.

BTG PLC

Recent Broker SP targets....

BTG Broker Views
Date Broker Recommendation Price Old target price New target price Notes

30 Jul Daniel Stewart Buy 360.35 - 482.00 Reiterates
24 Jul JP Morgan Cazenove Overweight 360.35 460.00 460.00 Reiterates

From Interims 17th of July



Louise Makin, Chief Executive Officer, commented: "We have made a strong start to the new financial year and there is good momentum across the business. Our Acute Care and Interventional Medicine sales and support teams are performing well and the Varisolve® team is fully engaged with the regulatory submission. During the second half of 2012, we anticipate top-line results from AstraZeneca's Phase IIb study of AZD9773 in severe sepsis and the first results from our PARAGON Bead® studies, which are an important step towards a planned regulatory Phase II study in metastatic colorectal cancer. We are in a good position to continue to build our business both through organic development and expansion and through licensing and acquisition activities."

Deutsche Bank have a target SP of 426P
... cant be bad.

BTG Broker Views
Date Broker Recommendation Price Old target price New target price Notes

30 Jul Daniel Stewart Buy 358.20 - 482.00 Reiterates
24 Jul JP Morgan Cazenove Overweight 358.20 460.00 460.00 Reiterates
18 Jul HB Markets Hold 358.20 - - Reiterates
18 Jul JP Morgan Cazenove Overweight 358.20 460.00 460.00 Reiterates
18 Jul Deutsche Bank Buy 358.20 424.00 426.00 Reiterates

Amazing chart.

Yes, agreed.
But it's all in the "Hope" camp - their P/E ratio (~110), is getting silly....

Treading water at the moment but ahead of the curve.

BRIEF BTG posts rise in H1 profit, sees full – year revenue at top end
11 Nov 2014 - 07:42

Nov 11 (Reuters) – BTG Plc

H1 revenue rose 25 percent to 191.2 million stg
Operating profit increased to £42.8m (h1 13/14: £25.0m)
Profit before tax £37.6m (h1 13/14: £32.7m)
Overall, we are in a good position to deliver our organic growth plans
Source text for Eikon: ... Further company coverage: BTG.L

BTG says long – awaited varicose vein treatment has positive debut
11 Nov 2014 - 09:19

(Adds CEO comments, shares)

Nov 11 (Reuters) – British drugs company BTG said it had started to roll out its varicose vein treatment to a positive response in the United States, as it said revenue for the year would be at the top end of forecasts.

Varithena, which has taken 18 years to reach the market after BTG acquired the technology, is an injectable foam that dissolves varicose veins rather than traditional techniques of stripping.

"The first commercial treatment was in August," Chief Executive Louise Makin said on Tuesday.

"The feedback from the physicians about the patients has been very good. We are very encouraged by that and everything is on track." She said the size of market for procedures reimbursed by insurers – for moderate to serious varicose veins – was about $250 million a year.

BTG was seeking approval to treat veins that were unsightly, but not yet painful, a market worth an additional $250 million, she said.

BTG, which also makes anti-venom drugs and products that deliver oncology drugs, posted a 25 percent rise in first-half revenue to 191.2 million pounds ($303 million), and a 15 percent rise in pretax profit to 37.6 million pounds.

The company said it expected its full-year revenue to be around the top end of its guidance of 330 million to 345 million pounds, despite adverse foreign exchange impacts.

Its shares were up 0.5 percent at 744 pence at 0851 GMT.

Panmure Gordon reiterates buy on BTG, target raised from 800p to 1035p.

paid 530 today growing self funding, bottom of chart, divi on the horizon, growing
upwards targets. directors good reputations , track records, ect the BB

Xmas 2015 very good Data to be realeased, 625p 19-11-15. ] much more 2016.
unable to confirm shire pharma director, at BTG ends BB

why would there be a further rns when their figures were released just a few days ago?
if it's just an additional or new director, that really isn't very exciting, whatever his cv

next numbers surely not due until mid may

Ah but the PE ratio is still over 60 DYOR and IC suggests they were misinformed ( " Cloudy" I read somewhere ), about the status of the Varisolve so there is still time and cost for the US insurance to accept they should be paying for this treatment.

It may also not help they are going to be seen as a British Company, when I suggest 4-years ago they should put in place plans to Mfr in the US.

I wasn't pleased to read LM had sold 25,000 shares ( DYOR ), and then been given ( TIN was it?), so she made a lot from previous investment -and then got a wad more.
Good on her, but it still leaves us with that PE ratio - and a relatively high-price for using Vs I understand, although that could be "negotiated" - resulting in less than projected profits...... Ah well, you can'y win 'em all...
There's not much time this year to recover (almost halving) the sp during 2015.
EDIT(14Nov2016)-1-year on and what's changed? Yawn...PE Ratio now 40...but no dividend, yet Co is awash with expensive Directors. ( BTW; Vs has been renamed ).
EDIT (11Dec2018)-Seems Americans Boston want to Buy has sent sp up to Yet PE is 210... meanwhile the business slumbers. Pity L-T UK Retail Investors won't see much benefit since the sp 823p is still not as high as from years ago.

sold today bad press telegraph boss arrested, S @ 616 will go back in, await news
target for buying unknown at this present moment BB

wrong on previouse, bb wrong BTG as i have sold , T to by 580 sorry BB